HOME   |    PDF   |   


Title

Imipramine versus escitalopram in generalized anxiety disorder

 

Authors

Yogesh Jain 1,*, Abhishek Mishra 2, Pawan Kumar Maurya 3, Hemlata Verma 4, Santenna Chenchula 1,* & Jay Prakash Agarwal 5

 

Affiliation

1Department of Pharmacology, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India; 2Department of Pharmacology, People's College of Medical Sciences and Research Centre, Bhopal, Madhya Pradesh, India; 3Department of Pharmacology, Shyam Shah Medical College (SSMC), Rewa, Madhya Pradesh, India; 4Department of Pharmacology, Gandhi Medical College, Bhopal, Madhya Pradesh, India; 5Department of Psychiatry, Gandhi Medical College, Bhopal, Madhya Pradesh, India; *Corresponding author

 

Email

Yogesh Jain - E-mail: pharmalove69@gmail.com
Abhishek Mishra - E-mail: withdrabhi@gmail.com
Pawan Kumar Maurya - E-mail: maurya.pg@gmail.com
Hemlata Verma - E-mail: drhemlataverma0505@gmail.com
Santenna Chenchula - E-mail: csanten7@gmail.com
Jay Prakash Agarwal - E-mail: drjaiprakash79@gmail.com
 

Article Type

Research Article

 

Date

Received October 1, 2026; Revised October 31, 2026; Accepted October 31, 2026, Published October 31, 2026

 

Abstract

Generalized anxiety disorder (GAD) is a common, chronic condition, and real-world comparative data on imipramine and escitalopram are limited. Therefore, it is of interest to compare their effectiveness and safety in outpatients with newly diagnosed GAD over 24 weeks. In this prospective observational study at Gandhi Medical College and Hamidia Hospital, Bhopal, 100 patients received imipramine (n=50) or escitalopram (n=50) at the treating physician's discretion. Anxiety was assessed with the Hamilton Anxiety Rating Scale (HAM-A) at baseline and at weeks 4, 12 and 24, and adverse drug reactions were recorded. Mean HAM-A score fell from 35.05 to 9.42 (73.1%) with imipramine and from 36.08 to 8.95 (75.2%) with escitalopram. Drowsiness was significantly more frequent with imipramine (36% vs 2%; P<0.001). Thus, both drugs produced comparable, substantial reductions in anxiety, with better tolerability for escitalopram; randomized trials are warranted.

 

Keywords

Generalized anxiety disorder (GAD), imipramine, escitalopram, hamilton anxiety rating scale, tricyclic antidepressant, selective serotonin reuptake inhibitor

 

Citation

Jain et al. Bioinformation 22(10): 6559-6564 (2026)

 

Edited by

P Kangueane

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.